Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer
Status:
Completed
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to determine if a new sustained-release 45 mg (depot)
formulation of leuprolide acetate will reduce serum testosterone levels to and maintain them
at medically castrate levels in subjects with prostatic adenocarcinoma.